c-LEcta’s DENARASE®, which is used for the necessary removal of nucleic acids from biopharmaceutical products, performed particularly well. DENARASE® is the most efficient technology on the market for meeting the stringent regulatory requirements for biopharmaceutical products. Sales of this product increased by 164% year-on-year in the first half of 2019. The other products in c-LEcta’s portfolio also performed very well and contributed to the positive development of the product business. c-LEcta now markets its self-developed products in 25 countries on four continents. In the first half of 2019, the company recorded more than 150 successful shipments.
For the second half of 2019, c-LEcta expects disproportionately strong sales growth, especially in the food segment. “Our goal in the past fiscal year was to further diversify our products and to develop from a project to a product company. In 2018, we therefore switched our structures to our own sales organization and a versatile product portfolio. This strategic change is now paying off. Our self-developed products are very well received in the market,” explains Dr. Marc Struhalla, CEO and founder of c-LEcta. CFO Thomas Pfaadt adds: “Our products for the food sector in particular will contribute to our growth in the second half of 2019. But we also expect the other products in our portfolio to continue their positive development. We have thus created the basis for raising our sales to a new level in the future.”